SAN DIEGO / Apr 17, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today it will report its financial results for its first quarter ended March 31, 2024, after the market close on Wednesday, May 8, 2024. Following the release... Read More

Helping hospital and emergency room customers respond to the critical demand for enhanced opioid testing SAN DIEGO / Apr 10, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System... Read More

Test Delivers on Company Commitment to Advance the Power of Diagnostics to Empower Patients with Rapid Results in Just 10 Minutes Savanna® RVP4+ Assay Research and Development Update SAN DIEGO / Apr 02, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho" or the “Company”) has received U.S. Food and... Read More

Aiding in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women SAN DIEGO / Mar 06, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in... Read More

SAN DIEGO / Feb 26, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced that members of its management team are scheduled to participate in the 45 th Annual Raymond James Institutional Investor Conference on March 5, 2024, in Orlando, FL.... Read More

The Board of Directors has terminated President and Chief Executive Officer, Douglas Bryant and appointed, on an interim basis, Michael Iskra as Chief Executive Officer and Robert Bujarski as President SAN DIEGO / Feb 21, 2024 / Business Wire / The Board of Directors (the “Board”) of QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”) has made significant decisions aimed to enhance operational efficiency,... Read More

Strong momentum in Labs business, with solid non-respiratory business growth and market share gains in industry-leading respiratory point-of-care portfolio Fourth Quarter 2023 Results and Highlights Revenue was $743 million, as reported: Non-respiratory revenue increased by 9% as reported and in constant currency Respiratory revenue decreased by 49% as reported and in constant currency GAAP net cash provided by operating... Read More

SAN DIEGO / Jan 23, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Tuesday, February 13,... Read More

SAN DIEGO / Dec 22, 2023 / Business Wire / QuidelOrtho Corporation (NASDAQ:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced that Douglas Bryant, President and Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, in San Francisco, CA,... Read More

Savanna delivers results in 25 minutes or less, improves clinical care, provides cost savings and delivers sample-to-result molecular testing across all laboratory settings SAN DIEGO / Dec 20, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) , a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received... Read More

SAN DIEGO / Nov 16, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Evercore ISI conference in Miami, FL, on November 30, 2023. Douglas Bryant, President and Chief... Read More

Highlights Third quarter revenue was $744 million, as reported, driven by strong respiratory demand and continued strength in non-respiratory businesses Non-respiratory revenue increased by 2% as reported and in constant currency, compared to the prior year period, driven by growth in the Labs business, which continues to perform to expectations Respiratory revenue decreased by 21% as reported and in constant currency,... Read More

Global Lyme Alliance (GLA), a leading nonprofit, produces chronic Lyme PSA with generous sponsorship from QuidelOrtho to ensure the broad visibility of this crucial message. STAMFORD, Conn. , Oct. 17, 2023 /PRNewswire/ -- In an inspiring and emotional display of solidarity for Lyme disease awareness, a striking public service announcement (PSA) has taken center stage in the heart of New York City's Times Square. The PSA, is... Read More

Earlier-than-expected demand for respiratory products in core markets drives strong preliminary performance Company to report third quarter 2023 financial results on November 1, 2023 SAN DIEGO / Oct 12, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and... Read More

SAN DIEGO / Sep 21, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the... Read More

SAN DIEGO / Aug 28, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023. Douglas... Read More

Highlights Second quarter revenue of $665.1 million increased by 8% as reported with non-respiratory revenue up 3% on a supplemental combined basis (up 4% in constant currency) and respiratory revenue down 74% on a supplemental combined basis Non-respiratory revenue driven by 9% constant currency growth in Labs business unit Second quarter GAAP loss per share of $(0.80); adjusted EPS of $0.26, an 88% decrease from prior year... Read More

Company receives top customer rating in the 2023 IMV ServiceTrak™ Awards SAN DIEGO / Jul 25, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has earned the No. 1 ranking in the diagnostics industry for Overall Customer... Read More

Strategic partnership will add middleware and data management solutions across the company’s diagnostics portfolio SAN DIEGO / Jul 24, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has entered into a software... Read More

SAN DIEGO / Jul 18, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2023 ended July 2, 2023, after the market close on Tuesday, August 8, 2023. Following... Read More

SAN DIEGO / May 23, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the William Blair 43 rd Annual Growth Stock Conference in Chicago, Illinois, on June 6, 2023. A... Read More

Highlights First quarter revenue of $846.1 million decreased by 16% as reported with non-respiratory revenue up 5% on a supplemental combined basis (up 7% in constant currency) and respiratory revenue down 72% on a supplemental combined basis Growth in non-respiratory revenue for the first quarter was driven by the Labs business unit, primarily due to heightened instrument delivery and testing demand First quarter GAAP EPS... Read More

QuidelOrtho to report first quarter 2023 financial results on May 3, 2023 SAN DIEGO / Apr 13, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the first quarter ended April 2, 2023. The... Read More

The integration of Quidel Corporation and Ortho Clinical Diagnostics joined two powerhouse networks providing leadership insights, professional development and mentoring to QWLN members around the globe SAN DIEGO / Mar 28, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and... Read More

SAN DIEGO / Mar 08, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted a De Novo request from the U.S. Food and Drug Administration (FDA), allowing the company to market its new Sofia® 2 SARS Antigen+ FIA. The Sofia 2... Read More

SAN DIEGO / Mar 02, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference in... Read More

MADISON, Wis. , Feb. 27, 2023 /PRNewswire/ -- ImageMover , a provider of Workflow Services for pharmacies, is proud to announce its partnership with QuidelOrtho (NASDAQ: QDEL), a leading provider of point-of-care diagnostic testing solutions, to bring a comprehensive solution for pharmacist-administered testing for a variety of illnesses, including COVID-19, influenza A+B, Lyme disease, strep throat, and RSV. This... Read More

SAN DIEGO / Feb 15, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter ended January 1, 2023. The Company reported total revenue for the fourth quarter of 2022 of $866.5 million, a... Read More

QuidelOrtho to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023 QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue results for the fourth quarter and full year ended January 1, 2023. The... Read More

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco beginning on January 9, 2023, with a presentation scheduled for 9:00 a.m. PST... Read More